In this review, we will highlight recent updates on the roles of chemokines, including CCL3, CCL25, CXCL1, CXCL16, and CX3CL1 (Figure 1), in the development of NAFLD and their blockade as a potential therapeutic approach. This evidence concerns the gene CXCL16 and metabolic dysfunction-associated steatotic liver disease.